Pharmaceuticals
Alphamab Oncology Announces IND Application for Innovative EGFR/HER3 Dual Payload Bispecific ADC JSKN021 was Officially Accepted by CDE
SUZHOU, China, March 13, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN021, an independently developed innovative dual payload bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, has been officially...
2026-03-13 09:53
4294
Emerald Clinical Trials Honored with 2026 Asia Pacific Biopharma Excellence Award for Outstanding Patient Recruitment & Engagement
SINGAPORE, March 12, 2026 /PRNewswire/ -- Emerald Clinical Trials
2026-03-12 21:02
3448
Nuance Pharma Announces Approval of Ohtuvayre® (ensifentrine) in Hong Kong SAR, China
Approval marks the second regulatory approval outside of the U.S. Food and Drug Administration, further expanding access to COPD patients in select Special Administrative Regions (SARs) in Greater China SHANGHAI, March 12, 2026 /PRNewswire/ -- Today, Nuance Pharma ("Nuance") announced that the H...
2026-03-12 15:52
2885
Building Resilient Rare Disease Support in Malaysia with Pharm-D Health Science's VALENS Specialised Nutrition
KUALA LUMPUR, Malaysia, March 12, 2026 /PRNewswire/ -- As Malaysia commemorates National Rare Disease Day and marks the launch of the National Policy for Rare Diseases, long-term, sustainable care for individuals living with rare, complex genetic conditions is now gaining growing attention and in...
2026-03-12 10:14
4967
Precision for Medicine Continues Asia-Pacific Expansion with Opening of Japan Office
New Tokyo office strengthens local partnerships, regulatory alignment and global integrations in the world's third largest pharmaceutical market BETHESDA, Md., March 12, 2026 /PRNewswire/ -- Precision for Medicine (Precision), a global leader in biomarker-driven clinical research and development...
2026-03-12 07:50
3113
Pierre Fabre Laboratories is exploring the potential of Artificial Intelligence to launch a new generation of clinical studies in dermo-cosmetics
From 100 to 600 patients: to support patients suffering from acne, Avène, Pierre Fabre Laboratories' leading brand, is strengthening the robustness of its clinical studies via data augmentation through Artificial Intelligence. TOULOUSE, France, March 11, 2026 /PRNewswire/ -- Avène, the leading br...
2026-03-11 23:40
4892
Alphamab Oncology Appoints Dr. Hongwei Wang as Chief Technology Officer
SUZHOU, China, March 11, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the appointment of Dr. Hongwei Wang as Chief Technology Officer (CTO). Dr. Wang will be responsible for the company's Process Development and Analytical Development Department, Production Department an...
2026-03-11 09:38
3641
Everest Medicines to Announce 2025 Full-Year Financial Results on March 26, 2026
SHANGHAI, March 10, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its financial re...
2026-03-10 18:40
3514
Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity
- ASC30 subcutaneous (SQ) depot formulation achieved statistically significant and clinically meaningful placebo-adjusted mean weight loss of 7.5% at week 16 after three monthly doses. - ASC30 SQ depot formulation maintained weight loss for the four months following the third and final mon...
2026-03-10 18:00
4225
K-pop Singer and Actress Kim Sejeong Named Global Brand Ambassador for 'REJURAN' and 'REJURAN COSMETICS'
GANGNEUNG, South Korea, March 10, 2026 /PRNewswire/ -- PharmaResearch Co., Ltd.
(CEO Jihoon Sohn) announced that singer and actress Kim Sejeong has been named
the new global brand ambassador for its flagship brands REJURAN® and REJURAN®
COSMETICS.
2026-03-10 16:03
5108
Codex Genetics Partners with C2N Diagnostics to Introduce the PrecivityAD2™ Blood Test in Hong Kong, Facilitating Access to Innovative Alzheimer's Disease Diagnostics
HONG KONG, March 10, 2026 /PRNewswire/ -- Codex Genetics, a leading precision diagnostics company headquartered in Hong Kong, today announces a strategic collaboration with C2N Diagnostics (C2N), a global leader in in advanced brain health diagnostics. The partnership will introduce the Precivit...
2026-03-10 09:33
3981
Everest Medicines Announces Commercial Launch and First Prescription for VELSIPITY® in Mainland China
SHANGHAI, March 9, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced the commercial launch of VELSIPITY® (...
2026-03-09 21:27
6564
Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Atopic Dermatitis
CHENGDU, China, March 9, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) and Harbour BioMed (HKEX: 02142) today announced that the National Medical Products Administration (NMPA) of China has approved the Investigational New Drug ...
2026-03-09 19:39
3943
G-NiiB GenieBiome and Ocean Park Conclude Gut Microbiome Education Programme
Two–Year Initiative Reaches Over 200,000 Parents and Children Student Artworks Reflect Early Understanding of Gut Health HONG KONG, March 9, 2026 /PRNewswire/ -- The gut is responsible for more than digestion and is often described as the body's "second brain." Research in recent years has highli...
2026-03-09 17:10
3619
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio
* Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs. * Transaction represents total equity value of approximately $2.5 billion. SURESNES, France and BRISBANE, Calif., Marc...
2026-03-07 02:30
10829
Sciwind Biosciences Announces Ecnoglutide Injection Approved by China's National Medical Products Administration (NMPA) for Chronic Weight Management
HANGZHOU, China, March 6, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind"), a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, announced today that China's National Medical Products Administration (NMPA) has ...
2026-03-06 14:39
3904
Empowering the SBMA Community: AnnJi Highlights Patient & Family Forum and Shares AJ201 Scientific Advancement at the 2026 KDA Conference
TAIPEI, March 4, 2026 /PRNewswire/ -- AnnJi Pharmaceutical Co., Ltd. (AnnJi, TWSE: 7754) announced its participation in the 2026 International Patient and Scientific Conference hosted by the Kennedy's Disease Association (KDA). Held between February 27 and March 2, the conference served as a prem...
2026-03-05 09:47
4487
MGI Tech Announces Acquisition of STOmics and CycloneSEQ to Deliver Integrated Long-Read, Short-Read and Spatial Omics Solutions
SHENZHEN, China, March 4, 2026 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive innovation in the life sciences, today announced the acquisition of STOmics and CycloneSEQ. It marks a significant milestone in MGI's "SEQALL+GLI+Omi...
2026-03-04 11:58
4779
Gene Solutions Announces Strategic Entry into Türkiye with Robust Real-World Evidence at the 2nd International Hereditary Cancers Congress 2026
In Partnership with ATC Genomics, the Company Presented One of Asia's Largest Real-World Datasets (n=12,281) for AI-Powered Multi-Cancer Early Detection (MCED) and Showcased its Clinically Validated ctDNA-Powered Oncology Portfolio Across the Full Cancer Continuum for High-Risk and Hereditary Pop...
2026-03-04 10:00
7122
Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases
* Antengene grants UCB worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, targeting B cell-related autoimmune diseases. * Antengene will receive USD 80 million of upfront and near-term milestone payments, and is e...
2026-03-04 06:00
5024
Week's Top Stories
Most Reposted
Tetra Pak Opens Product Development Centre in Thailand, Unlocking A World of Possibilities for Food and Beverage Innovators Across Asia Pacific
[Picked up by 316 media titles]
2026-03-27 11:15
Indonesia's P2P Lending Grows 25%, JULO Strengthens Credit Quality
[Picked up by 300 media titles]
2026-03-26 18:18
From Doomscroll to Page-Turner: BookXcess Launches The Brain Un-Rot Library to Help Rebuild a Generation's Focus
[Picked up by 298 media titles]
2026-03-31 13:53
New Swisslog APeC structure delivers greater resources to Southeast Asian customers
[Picked up by 288 media titles]
2026-03-31 11:25
ART CENTRAL COMMENCES DISCOVERY-LED ELEVENTH EDITION
[Picked up by 280 media titles]
2026-03-25 16:51
